Hennion & Walsh Asset Management Inc. Grows Stake in Novo Nordisk A/S (NYSE:NVO)

Hennion & Walsh Asset Management Inc. increased its stake in Novo Nordisk A/S (NYSE:NVO) by 9.4% in the 4th quarter, HoldingsChannel reports. The fund owned 19,742 shares of the company’s stock after acquiring an additional 1,701 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $1,698,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Raymond James & Associates grew its position in Novo Nordisk A/S by 1.0% in the third quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock worth $419,939,000 after acquiring an additional 36,223 shares in the last quarter. Natixis Advisors LLC grew its position in Novo Nordisk A/S by 2.7% in the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after acquiring an additional 80,070 shares in the last quarter. International Assets Investment Management LLC lifted its stake in Novo Nordisk A/S by 10,608.4% in the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock worth $215,942,000 after purchasing an additional 1,796,635 shares during the last quarter. DSM Capital Partners LLC lifted its stake in Novo Nordisk A/S by 257,816.0% in the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after purchasing an additional 1,593,303 shares during the last quarter. Finally, LPL Financial LLC lifted its stake in Novo Nordisk A/S by 3.6% in the third quarter. LPL Financial LLC now owns 1,362,782 shares of the company’s stock worth $162,266,000 after purchasing an additional 47,496 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

NVO has been the subject of several analyst reports. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. Finally, StockNews.com downgraded shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Buy” and an average target price of $140.20.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $78.74 on Friday. The firm has a market capitalization of $353.33 billion, a PE ratio of 25.48, a price-to-earnings-growth ratio of 0.92 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15. The company’s fifty day moving average price is $97.76 and its 200-day moving average price is $117.23.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.